Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.
Study Type
OBSERVATIONAL
Enrollment
35,002
Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Radiotherapy versus no radiotherapy.
Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
Chemotherapy versus no chemotherapy.
Type of surgery (partial mastectomy, mastectomy, other).
Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
Screening detected tumor (yes, no).
Menopausal status (premenopausal, postmenopausal).
Tumor size (≤5 mm, 6-≤10 mm).
ER-status (positive, negative).
Tumor grade (1, 2, 3).
HER2-status (positive, negative).
Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
N-status (N0, N1).
Karolinska Instiutet
Solna, Sweden
Breast cancer specific death
Time frame: January 1, 1977 to December 31, 2014
Death from any cause
Time frame: January 1, 1977 to July 30, 2016
Metachronous breast cancer
Ipsilateral or contralateral breast cancer
Time frame: January 1, 1977 to July 30, 2016
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.